SHSE:688505's Forward Dividend Yield % is ranked better than 53.16% of 506
companies
in the Drug Manufacturers industry
Industry Median: 2.025
vs SHSE:688505: 0.63
During the past 12 months, Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co's average Dividends Per Share Growth Rate was -66.70% per year.
During the past 3 years, the average Dividends Per Share Growth Rate was -26.90% per year.
During the past 5 years, the average Dividends Per Share Growth Rate was -9.50% per year.
During the past 10 years, the average Dividends Per Share Growth Rate was 3.10% per year.
During the past 13 years, the highest 3-Year average Dividends Per Share Growth Rate of Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co was 31.90% per year. The lowest was -26.90% per year. And the median was 7.40% per year.
The growth rate is calculated with least square regression.
For more information regarding to dividend, please check our Dividend Page.
Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co (SHSE:688505) Forward Dividend Yield % Explanation
Over the long term, the return from dividends has been a significant contributor to the total returns produced by equity securities. Studies by Elroy Dimson, Paul Marsh, and Mike Staunton of Princeton University (2002) found that a market-oriented portfolio, which included reinvested dividends, would have generated nearly 85 times the wealth generated by the same portfolio relying solely on capital gains.
Dividends may also qualify a lower tax rate for investors.
In dividends investing, Payout Ratio and Dividend Growth Rate are the two most important variables for consideration. A lower payout ratio may indicate that the company has more room to increase its dividends.
Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co Forward Dividend Yield % Related Terms
SHSE:688505 vs ZTS, UTHR: Forward Dividend Yield % Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co's Forward Dividend Yield %, along with its competitors' market caps and Forward Dividend Yield % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co Forward Dividend Yield % vs Drug Manufacturers Industry
Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co Forward Dividend Yield % Calculation
Dividend Yield measures how much a company pays out in dividends each year relative to its share price.
Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co Recent Full-Year* Dividend History
Amount
Ex-date
Record Date
Pay Date
Type
Frequency
Forex Rate
CNY 0.030000
2025-07-18
2025-07-17
2025-07-18
Cash Dividend
semi-annually
CNY:CNY 1.000000
* GuruFocus has an internal rule that if the most recent dividend payment frequency is at least 4 times a year, then the full year will be calculated according to the frequency of payment or the one-year time frame, whichever is stricter.
* GuruFocus converts dividend currency to local traded share price currency in order to calculate dividend yield. Please refer to the last column "Forex Rate" in the above table.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
What does a Forward Dividend Yield % of 0.63% mean?
Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co (SHSE:688505) has a Forward Dividend Yield % of 0.63% as of Jul. 05, 2026. Forward dividend yield is the ratio of company's expected dividends to the share price. View historical data on Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co and its competitors. According to the industry distribution chart, Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co ranks #237 out of 506 companies in the Drug Manufacturers industry, placing it in the top 46.8%.
Is Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co's Forward Dividend Yield % too high?
Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co's current Forward Dividend Yield % is 0.63%. The Drug Manufacturers industry median Forward Dividend Yield % is 2.03. Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co's value of 0.63% is 68.9% below this industry median. Based on the distribution chart, Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co ranks #237 out of 506 companies in the Drug Manufacturers industry, which is above the industry midpoint. Overall, Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co has a GF Score™ of 67/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co's Forward Dividend Yield % compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co ranks #237 out of 506 companies for Forward Dividend Yield %. This puts Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co in the upper half of its industry. The industry median Forward Dividend Yield % is 2.03. Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co's value of 0.63% is 68.9% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Forward Dividend Yield % for a Drug Manufacturers company?
The median Forward Dividend Yield % among Drug Manufacturers companies is 2.03, based on 506 companies in the industry. Companies in the top quartile (top 25%) have a Forward Dividend Yield % significantly above this median, while those in the bottom quartile fall well below. However, Forward Dividend Yield % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co's current Forward Dividend Yield % of 0.63% is 68.9% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Forward Dividend Yield % mean?
A high Forward Dividend Yield % can signal that a stock is expensive relative to its fundamentals. Forward dividend yield is the ratio of company's expected dividends to the share price. View historical data on Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co and its competitors. For the Drug Manufacturers industry, the median Forward Dividend Yield % is 2.03 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co's current Forward Dividend Yield % is 0.63%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co stock overvalued right now?
Based on GuruFocus' analysis, Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co (SHSE:688505) is currently considered Modestly Overvalued. The stock's GF Value™ is ¥6.84, compared to a current price of ¥7.88 — trading 15.2% above its estimated fair value. The current Forward Dividend Yield % is 0.63% and 68.9% below the Drug Manufacturers industry median of 2.03. Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co's overall GF Score™ is 67/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Forward Dividend Yield % calculated?
Forward Dividend Yield % is calculated from a company's financial statements. For Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co (SHSE:688505), the current Forward Dividend Yield % is 0.63% as of Jul. 05, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co (SHSE:688505) Overvalued in 2026?
Based on GuruFocus' analysis, Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co stock appears to be overvalued.
The current stock price of ¥7.88 is trading 15.2% above its estimated GF Value™ of ¥6.84.
GuruFocus considers Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co to be Modestly Overvalued.
Key valuation signals for SHSE:688505:
Forward Dividend Yield %: 0.63%
GF Value™: ¥6.84 vs. price of ¥7.88 (15.2% above fair value)
Industry Position: 68.9% below the Drug Manufacturers median (#237 of 506)
No single metric tells the full story. See the SHSE:688505 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co Business Description
Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co Ltd is engaged in the research, development, manufacturing, and sale of biopharmaceutical products. Its product portfolio includes ALA (Aminolevulinic acid Hydrochloride); FuMeiDa and Libord. The company has launched it's four types of photodynamic drugs in China market, namely hematoporphyrin, aminolevulinic acid hydrochloride, Verteporfin and Hemoporfin. Geographically, it derives revenue from Mainland China.
67GF Score
Get the complete analysis for SHSE:688505
Forward Dividend Yield % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SHSE:688505 has been successfully added to your 